Daily Endocrinology Research Analysis
Across endocrinology today, a meta-analysis of 21 randomized trials shows that using continuous glucose monitoring to guide nutrition and lifestyle meaningfully improves glycemia and weight in type 2 diabetes. A large diagnostic genetics study demonstrates that CYP21A2 promoter sequencing refines diagnosis and genotype–phenotype correlation in 21-hydroxylase deficiency. Mechanistically, new human and in vitro evidence links parathyroid hormone signaling to NOX2-mediated platelet activation in po
Summary
Across endocrinology today, a meta-analysis of 21 randomized trials shows that using continuous glucose monitoring to guide nutrition and lifestyle meaningfully improves glycemia and weight in type 2 diabetes. A large diagnostic genetics study demonstrates that CYP21A2 promoter sequencing refines diagnosis and genotype–phenotype correlation in 21-hydroxylase deficiency. Mechanistically, new human and in vitro evidence links parathyroid hormone signaling to NOX2-mediated platelet activation in postsurgical hypoparathyroidism, indicating potential thrombotic risk during PTH therapy.
Research Themes
- Digital glucose monitoring to individualize lifestyle therapy in T2D
- Genetic diagnostics refinement for congenital adrenal hyperplasia
- Hormone–platelet redox signaling and cardiovascular risk in hypoparathyroidism
Selected Articles
1. Continuous Glucose Monitoring to Guide Lifestyle Choices With a Focus on Nutrition in the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Across 21 RCTs (n=2734), CGM-guided nutrition/lifestyle interventions significantly reduced HbA1c by 0.46%, increased time-in-range by 7.18%, lowered time-above-range, fasting glucose, and body weight by about 2 kg. Evidence certainty was moderate for key outcomes and lower for mean CGM glucose and variability.
Impact: This synthesis provides high-level evidence that CGM can be used not only for monitoring but to actively guide lifestyle choices, yielding clinically meaningful glycemic and weight benefits in T2D.
Clinical Implications: Clinicians can integrate CGM-driven feedback into nutrition counseling and lifestyle programs for T2D to achieve additional HbA1c reduction and weight loss. Implementation should include patient education and access to CGM, with attention to heterogeneity and adherence.
Key Findings
- Meta-analysis of 21 RCTs (n=2734) showed HbA1c reduction of −0.46% (95% CI −0.71, −0.22).
- Time-in-range (70–180 mg/dL) increased by 7.18% and time-above-range decreased by 7.32%.
- Fasting glucose and body weight decreased (−7.86 mg/dL and −2.06 kg, respectively).
Methodological Strengths
- Included only randomized controlled trials with CGM-guided behavior change components.
- Random-effects meta-analysis with GRADE certainty assessment.
Limitations
- Heterogeneity in intervention components and education intensity across trials.
- Lower certainty for mean CGM glucose and glycemic variability outcomes.
Future Directions: Head-to-head trials comparing CGM-guided nutrition-only vs multicomponent programs, cost-effectiveness analyses, and studies in diverse healthcare settings to define optimal implementation strategies.
OBJECTIVES: The objective of this systematic review and meta-analysis was to synthesize evidence from randomized controlled trials (RCTs) evaluating the use of continuous glucose monitoring (CGM) to guide lifestyle choices, particularly nutrition, in the management of T2D. METHODS: PubMed and Cochrane CENTRAL were searched from inception to June 6, 2025. Randomized controlled trials were included if their intervention involved the use of a CGM device and education or feedback intended to modify nutrition choices, either as part of a nutrition intervention or a multicomponent lifestyle intervention. Random-effects meta-analyses were performed, and certainty of evidence was rated in alignment with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: A total of 21 RCTs involving 2734 adults in groups of interest were included, with 20 RCTs eligible for meta-analysis. Results from meta-analysis showed statistically significant improvements in HbA1c (MD: -0.46%, 95% CI: -0.71, -0.22), time in range (TIR) 70-180 mg/dL (MD: 7.18%, 95% CI: 2.77, 11.58), time above range (TAR) >180 mg/dL (MD: -7.32%, 95% CI: -12.98, -1.66), fasting glucose (MD: -7.86 mg/dL, 95% CI: -15.06, -0.65), body weight (MD: -2.06 kg, 95% CI: -3.74, -0.38), with moderate certainty of evidence, and for mean CGM glucose (MD: -11.57 mg/dL, 95% CI: -22.58, -0.56), and standard deviation (SD) glucose (MD: -4.06 mg/dL, 95% CI: -6.54, -1.58), with low certainty of evidence. No statistically significant differences were found for other outcomes, typically with low certainty of evidence. CONCLUSIONS: Findings from this systematic review and meta-analysis support the use of CGM as a tool to guide lifestyle choices with a focus on nutrition in the management of T2D, with significant benefits related to glycemia and body weight.
2. PTH-driven modulation of platelet activity via the NOX2 pathway in postsurgical hypoparathyroidism.
HypoPT patients displayed heightened platelet activation, oxidative stress, and faster thrombus formation versus controls. PTH(1-34) therapy further amplified these changes. In vitro, PTH(1-34) enhanced platelet aggregation only in HypoPT platelets via a PTH1R–Ca2+–PKC–NOX2 pathway, indicating a disease-specific pro-thrombotic signaling axis.
Impact: Revealing a direct, mechanistic link between PTH signaling and NOX2-dependent platelet activation reframes cardiovascular risk in HypoPT and raises safety considerations for PTH analog therapy.
Clinical Implications: HypoPT management should include cardiovascular risk surveillance, particularly when initiating or maintaining PTH analog therapy; monitoring platelet activation/oxidative stress markers and optimizing traditional risk factors may be warranted.
Key Findings
- HypoPT patients had increased platelet activation, oxidative stress, and accelerated thrombus formation compared with controls.
- PTH(1-34) therapy further amplified platelet activation and oxidative stress in HypoPT.
- In vitro, PTH(1-34) activated platelets from HypoPT patients via PTH1R, intracellular Ca2+ release, PKC activation, and NOX2-dependent ROS generation.
Methodological Strengths
- Use of age- and sex-matched controls and multi-modal platelet assays with oxidative stress biomarkers.
- Mechanistic dissection of PTH1R–PKC–NOX2 signaling with both ex vivo human platelets and in vitro stimulation.
Limitations
- Small sample size and cross-sectional design limit causal inference and generalizability.
- Subgroup on PTH therapy (n=5) is underpowered and requires confirmation in larger cohorts.
Future Directions: Prospective studies to evaluate thrombotic events under PTH therapy, exploration of antiplatelet or antioxidant strategies, and validation of NOX2-related biomarkers as risk stratifiers in HypoPT.
OBJECTIVE: Postsurgical chronic hypoparathyroidism (HypoPT) has been linked to an increased cardiovascular risk, but the underlying pathophysiological mechanisms remain incompletely understood. Emerging evidence suggests a potential direct role of parathyroid hormone (PTH) in modulating platelet function and oxidative stress, both contributors to atherothrombosis. Our study aimed to investigate the impact of PTH on platelet function and activation, with a particular focus on NOX2-mediated platelet activation in patients with HypoPT. METHODS: We conducted a cross-sectional study involving 24 patients with HypoPT and 40 age- and sex-matched healthy controls. Clinical, biochemical, and platelet function parameters were assessed. In a subgroup of five HypoPT patients, changes were evaluated after 24 months of PTH (1-34) therapy. Platelet aggregation, oxidative stress biomarkers (sNOX2-dp, H
3. Accurate diagnosis of congenital adrenal hyperplasia due to CYP21A2 variants requires promoter analysis.
In 1,279 individuals undergoing CYP21A2 testing, promoter variants were found in 7.0% overall and 12.1% of 21-OHD patients. A promoter-inclusive conversion with p.Pro31Leu often produced a simply virilizing phenotype in trans with a classic allele. Promoter sequencing identified CAH or carrier status that conventional coding-region sequencing would have missed.
Impact: By demonstrating clinically meaningful frequencies and phenotypic effects of CYP21A2 promoter variants, this study makes a compelling case to include promoter sequencing in routine CAH diagnostics.
Clinical Implications: Diagnostic workflows for 21-OHD should add CYP21A2 promoter analysis to improve genotype–phenotype concordance, detect carriers, and refine counseling and management, particularly when only one pathogenic coding variant is identified.
Key Findings
- CYP21A2 promoter variants were present in 7.0% of all tested individuals and 12.1% of 21-OHD patients.
- A promoter-inclusive conversion with exon 1 p.(Pro31Leu) in 21 patients often led to a simply virilizing phenotype when in trans with a classic allele.
- Promoter sequencing uncovered CAH or carrier status in individuals who would be missed by conventional coding-region sequencing.
Methodological Strengths
- Large tertiary-center cohort with comprehensive CYP21A2 genotyping including promoter region.
- Systematic phenotype correlation enabling identification of diagnostic discrepancies.
Limitations
- Retrospective design in a single referral center may limit generalizability.
- Functional assays of promoter variants were not reported.
Future Directions: Prospective validation across diverse populations, functional characterization of promoter variants, and cost-effectiveness analyses of adding promoter sequencing to routine CAH panels.
OBJECTIVE: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disease mostly caused by compound heterozygous pathogenic CYP21A2 variants. CYP21A2 promoter analysis is frequently not included in routine diagnostics, but could explain discrepancies in the usually good genotype-phenotype correlation. Here we investigate frequency and type of CYP21A2 promoter variants and their influence on 21-OHD phenotype. DESIGN: Observational cohort study in a tertiary referral center and accredited genetic laboratory. METHODS: CYP21A2 genotyping including promoter analysis was performed and clinical/biochemical parameters were retrospectively collected in 1279 individuals undergoing routine diagnostic CYP21A2 genotyping. RESULTS: We detected promoter variants in 89 individuals (7.0%). Of 207 patients with 21-OHD, 12.1% had promoter variants. A large conversion including the promoter (c.-126C>T, c.-113G>A, c.-110T>C, c.-103A>G) and p.(Pro31Leu) in exon 1 was found in 21 patients and led to a mostly simply virilizing phenotype when occurring in trans with another classic allele. Promoter variants were observed in CAH patients with only 1 known pathogenic variant (n = 4) and in clinically unaffected individuals with no other CYP21A2 variant (n = 6); conventional sequencing without the promoter region would not have suggested CAH or 21-OHD carrier status in these individuals (n = 10). CONCLUSIONS: Non-benign promoter variants occur frequently in individuals with 21-OHD and clinically unaffected carriers. Promoter variants can aggravate clinical presentation in 21-OHD and can explain cases with discrepant genotype and phenotype. Inclusion of CYP21A2 promoter analysis in diagnostic procedures can improve accuracy of diagnosis, management and genetic counseling in patients with 21-OHD and their families.